2
Clinical Trials associated with Mesenchymal stem cell therapy for meniscal repair ( Mesoblast)Phase 2B: Randomized Double-Blinded Clinical Study of Chondrogen for Treatment of Knee Osteoarthritis
Primary osteoarthritis is a debilitating disease characterized by extensive damage to the joints and excruciating pain leading to loss of activity and depression. Despite advances in diagnosis, the quest for the development of a disease-modifying osteoarthritis drug has proven unsuccessful. Human cartilage only has limited regenerative potential. Transplantation is a promising strategy given the high proliferative capacity of MSCs and their potential to differentiate into cartilage-producing cells - chondrocytes. The acquisition of MSC does not require invasive surgical intervention or cartilage extraction from other sites as required by other cell-based strategies. The investigators inject allogeneic human mesenchymal stem cells to the cartilage lesions in patients via intra-articular injection method, and to investigate the efficacy and safety.
A Long-Term Follow-up Study of Chondrogen - Adult Human Stem Cells Delivered by Intra-articular Injection Following Meniscectomy in Subjects 18-60 Years
The objective of the present study is to establish the long-term safety of an intra-articular injection of human mesenchymal stem cells (hMSCs) (Chondrogen).
100 Clinical Results associated with Mesenchymal stem cell therapy for meniscal repair ( Mesoblast)
100 Translational Medicine associated with Mesenchymal stem cell therapy for meniscal repair ( Mesoblast)
100 Patents (Medical) associated with Mesenchymal stem cell therapy for meniscal repair ( Mesoblast)
100 Deals associated with Mesenchymal stem cell therapy for meniscal repair ( Mesoblast)